STSA-1002 Injection Placebo

DRUG2 trials

Sponsors

Staidson (Beijing) Biopharmaceuticals Co., Ltd

Conditions

Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndrome (ARDS)

Phase 1

To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

CompletedNCT06038916

Staidson (Beijing) Biopharmaceuticals Co., LtdAcute Respiratory Distress Syndrome

Start: 2023-12-09End: 2025-04-27Updated: 2025-07-11

Phase 3

To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

RecruitingNCT07208591

Staidson (Beijing) Biopharmaceuticals Co., LtdAcute Respiratory Distress Syndrome (ARDS)

Start: 2025-10-31End: 2026-10-31Target: 406Updated: 2026-01-02